Literature DB >> 11060961

Diagnosis and treatment of gastroesophageal reflux disease in the elderly.

F C Ramirez1.   

Abstract

Gastroesophageal reflux disease poses special diagnostic and therapeutic challenges in the elderly. These patients may not report the classic symptoms of dysphagia, chest pain, and heartburn, and they are more likely to develop severe disease and complications such as esophageal ulceration and bleeding. Therapeutic options include lifestyle changes, medication, and surgery. Polypharmacy and changes in renal, hepatic, and gastrointestinal function can complicate treatment. Proton pump inhibitors can help optimize disease management. The most common primary presenting symptoms of GERD in the elderly are regurgitation, dysphagia, dyspepsia, vomiting, and noncardiac chest pain, rather than heartburn. Because the elderly commonly take multiple drugs for various comorbidities, drug interactions and treatment responses must be carefully assessed in this patient population. Nonpharmacologic measures may be helpful but often do not relieve nighttime GERD symptoms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11060961     DOI: 10.3949/ccjm.67.10.755

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  3 in total

Review 1.  Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors:  Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.

Authors:  Majid Vakily; Ronald D Lee; Jingtao Wu; Lhanoo Gunawardhana; Darcy Mulford
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 3.  Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update.

Authors:  Ralph-Steven Wedemeyer; Henning Blume
Journal:  Drug Saf       Date:  2014-04       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.